Skip to main content
NAVCO Pharmaceuticals logo

NAVCO Pharmaceuticals — Investor Relations & Filings

Ticker · NAV ISIN · CA63942R1091 LEI · 8945003WKDH61M8UB963 TSXV Manufacturing
Open in API
Filings indexed 199 across all filing types
Latest filing 2023-08-30 Regulatory Filings
Country CA Canada
Listing TSXV NAV

About NAVCO Pharmaceuticals

https://www.navcopharma.com/

NAVCO Pharmaceuticals is a biotechnology company specializing in the research, development, and commercialization of nanotechnology products and materials. The company utilizes proprietary Computerized Nano-meter Algorithms to create innovative solutions for anti-viral, anti-fungal, and anti-bacterial treatments. NAVCO focuses on developing supplemental and therapeutic consumer health and wellness products. A key offering is the BioActive™ line, which includes non-toxic, non-flammable, and alcohol-free hand cleansers, creams, and surface disinfectants designed to provide extended protection against germs and microorganisms. These nanotechnology products are marketed across various sectors, including medicine and textiles, providing next-generation protection solutions for multiple industries.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate by the CFO of Navco Pharmaceuticals Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2023. The document is primarily an officer certification letter and does not contain actual financial statements or substantive financial data. It references the interim filings but does not include them. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (3013 characters), consistent with a certification letter rather than a full report.
2023-08-30 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate by the CEO of Navco Pharmaceuticals Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2023. The document is a certification letter and does not contain actual financial statements or substantive financial data. It references an interim report but is itself a certification of that report, not the report itself. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS). The document length is short (3014 characters), consistent with a certification letter rather than a full interim report.
2023-08-30 English
Interim MD&A - English.pdf
Management Reports Classification · 100% confidence The document is titled 'Management Discussion & Analysis' (MD&A) for the nine-month period ended June 30, 2023. It contains detailed financial performance discussion, operational results, liquidity and capital resources, quarterly and annual financial summaries, and forward-looking statements. The content is consistent with a Management Discussion & Analysis report, which provides management's detailed explanation of financial results, business trends, and outlook. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. Therefore, the appropriate classification is 'Management Reports' (MDA).
2023-08-30 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document contains detailed financial statements including a statement of financial position, statement of loss and comprehensive loss, statement of changes in equity, and statement of cash flows for the period ended June 30, 2023. It explicitly mentions that these are interim condensed consolidated financial statements and includes a notice of no auditor review, which is typical for interim reports. The presence of actual financial data and analysis for a period shorter than a full fiscal year (six months ended June 30, 2023) confirms this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). Q3 2023
2023-08-30 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Interim Financial Statements' for the three and nine months ended March 31, 2023, and contains detailed unaudited financial statements including statements of financial position, operations, changes in equity, cash flows, and notes. It explicitly states compliance with International Accounting Standard 34 for interim financial reporting. The content includes substantive financial data and analysis for a period shorter than a full fiscal year (nine months). Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2023
2023-05-31 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Management’s Discussion and Analysis' (MD&A) for the nine months ended March 31, 2023, which is a detailed explanation of the company's financial results, business trends, and outlook for a period shorter than a full fiscal year. It contains substantive financial data, including working capital, net income/loss, revenues, expenses, liquidity, capital resources, and quarterly results. The document references condensed interim financial statements prepared under IFRS, indicating it is an interim report. The length of the document (15,000 characters) and the detailed financial discussion confirm it is not merely an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2023
2023-05-31 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.